comparemela.com

Latest Breaking News On - Za zhi - Page 2 : comparemela.com

Frontiers | Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia

Mucopolysaccharidosis VI (MPS VI) is an autosomal recessive lysosomal storage disease caused by mutations in the arylsulfatase B gene (ARSB) and consequent deficient activity of ARSB, a lysosomal enzyme involved in glycosaminoglycan (s) (GAGs) metabolism. Here we present the results study of ARSB DNA analysis in MPS VI patients in the Russian Federation (RF) and other republics of Former Soviet Union. In a cohort of 68 patients (57 families) with MPS VI, a total of 28 different pathogenic alleles were found. The most prevalent nucleotide changes included c.194C>T (Ser65Phe) and c.454C>T (Arg152Trp). Five pathogenic alleles were novel, not previously reported (с.304C>G, c.533A>G, c.941T>C, c.447 456del10, С.990 1003del14). The nucleotide variant c.454C>T (Arg152Trp) was prevalent allele among Slavic Russian patients. The nucleotide variant c.194C>T (Ser65Phe) was found only in MPS VI families from the Republic of Dagestan. Based on the analysis of dry blood spots

Frontiers | The Relevance of Genomic Epidemiology for Control of Tuberculosis in West Africa

Frontiers | The Relevance of Genomic Epidemiology for Control of Tuberculosis in West Africa
frontiersin.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from frontiersin.org Daily Mail and Mail on Sunday newspapers.

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.